Tumor Shrinkage With Lanreotide Autogel 120 mg as Primary Therapy in Acromegaly: Results of a Prospective Multicenter Clinical Trial-Reference-Cited by-同舟云学术

Tumor Shrinkage With Lanreotide Autogel 120 mg as Primary Therapy in Acromegaly: Results of a Prospective Multicenter Clinical Trial

Author:

Caron Philippe J.¹,Bevan John S.²,Petersenn Stephan³,Flanagan Daniel⁴,Tabarin Antoine⁵,Prévost Gaëtan⁶,Maisonobe Pascal⁷,Clermont Antoine⁷,

Affiliation:

1. Department of Endocrinology and Metabolic Diseases (P.J.C.), Centre Hospitalier Universitaire Larrey, F-31059 Toulouse, France;

2. Department of Endocrinology (J.S.B.), Aberdeen Royal Infirmary, Aberdeen AB25 2ZP, United Kingdom;

3. ENDOC Center for Endocrine Tumors (S.P.), 20357 Hamburg, Germany;

4. Department of Endocrinology (D.F.), Derriford Hospital, Plymouth PL6 8DH, United Kingdom;

5. Department of Endocrinology, Diabetes, Metabolic Diseases, and Nutrition (A.T.), University of Bordeaux 2, CHU Bordeaux, 33076 Bordeaux, France;

6. Department of Endocrinology, Diabetes, and Metabolic Diseases (G.P.), CHU Rouen, 76031 Rouen, France;

7. Ipsen Pharma (P.M., A.C.), 92100 Boulogne-Billancourt, France

Publisher

The Endocrine Society

Subject

Biochemistry (medical),Clinical Biochemistry,Endocrinology,Biochemistry,Endocrinology, Diabetes and Metabolism

Link

Reference23 articles.

Cited by 158 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

2. Current role of pasireotide in the treatment of acromegaly;Best Practice & Research Clinical Endocrinology & Metabolism;2024-07

3. Treatment of acromegaly with oral octreotide;Best Practice & Research Clinical Endocrinology & Metabolism;2024-07